-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Enliven Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2019 to Q2 2024.
- Enliven Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $4.65M, a 36.3% increase year-over-year.
- Enliven Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $14.7M, a 142% increase year-over-year.
- Enliven Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $11.9M, a 958% increase from 2022.
- Enliven Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $1.13M, a 5032% increase from 2021.
- Enliven Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $22K, a 93.5% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)